| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9600783 | Alzheimer's & Dementia | 2005 | 7 Pages |
Abstract
The technical development of biomarkers that are used for presymptomatic AD diagnosis and for longitudinally measuring disease severity is evolving rapidly. Ethical and privacy considerations must be made before such biomarkers can be applied routinely to asymptomatic populations.
Keywords
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
John C. Morris, A. Kimberly, K. Quaid, David M. Holtzman, Kejal Kantarci, Jeffrey Kaye, Eric M. Reiman, William E. Klunk, Eric R. Siemers,